> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hospira Epogen/Procrit Biosimilar Heads to Panel Meeting
- URL: https://www.fdaweb.com/hospira-epogen-procrit-biosimilar-heads-to-panel-meeting/
- Published: 2017-04-19T12:00:00.000Z
- Updated: 2026-09-14T22:18:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138490

*Federal Register* notice: FDA has announced a 5/25 Oncologic Drugs Advisory Committee meeting that will discuss a Hospira BLA for a proposed biosimilar product referencing Amgen’s Epogen/Procrit (epoetin alfa), indicated for treating anemia due to certain illnesses. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-04-18/pdf/2017-07772.pdf?ref=fdaweb.com).